Rigel Pharmaceuticals focuses on innovative therapeutics for hematological conditions and cancers, with FDA-approved products Tavalisse, Rezlidhia, and Gavreto targeting specific diseases. RIGL’s pipeline also includes promising drug candidates like R289, targeting lower-risk myelodysplastic syndromes and other kinase-related diseases. Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is a biotechnology company focused on discovering...

Existing home sales fell for a fourth straight month in June, while the median price reached a new record high. Existing homes have been experiencing a consistent downward trajectory over the past two years, with monthly sales declining 23 of the past 29 months. Existing home sales fell for a...

Biopharmaceutical company Verastem Oncology (NASDAQ:VSTM) priced of an underwritten public offering of ~13.33M shares and warrants to purchase up to ~13.33M shares at a combined offering price to the public of $3.00 per share. The gross proceeds from the offering are expected to be ~$55M. Net proceeds from the public...

Financial software company OneStream (OS) priced its initial public offering of 24.5M shares at $20.00 per share. The shares are expected to begin trading on the Nasdaq on July 24, 2024, under the symbol "OS." The offering consists of ~18.05M shares to be sold by OneStream and ~6.45M shares to...

Agenus is a small biotech company focused on developing cancer treatments, with a history of poor stock performance and financial struggles. The company's primary assets in its pipeline are Botensilimab and Balstilimab, which have shown limited efficacy in pre-clinical and clinical trials. Introduction. Agenus Inc. (NASDAQ:AGEN) is a small biotech...

Although not a computer science expert, I know enough to understand that AI doesn’t mean cognition, it really means “more” and “better”. Accordingly, companies tied to selling “more” and “better” will be the ones to truly profit from AI. Computers are...

CRWD’s faulty sensor update crashed 8.5M devices, disrupting aviation, healthcare, retail, and media sectors, leading to a 30% stock price drop since June. Despite short-term losses, CRWD remains a Buy due to operational excellence and a robust cybersecurity market. Potential for a 14% CAGR with a $970 price target by 2034.

Owens & Minor shares rose 7.6% after a major acquisition announcement and positive second quarter results. Preliminary results show revenue growth and improved profits. July 23rd ended up being a pretty big day for shareholders of Owens & Minor (NYSE:OMI). Shares of the company closed up 7.6% after two different press releases came out. The first involved news that the company was making a major acquisition. This particular purchase, based on the data available, looks like it will be truly transformative and will further the company's goal of significantly growing its Patient Direct operations over the next few years. And the second ended up being preliminary guidance covering the second quarter of the company's 2024 fiscal year. Overall, that data came in fairly positive compared to what analysts had been anticipating.

Verizon's shares dropped 6% after missing Q2 revenue targets, but the telecom nonetheless saw growth in wireless, broadband and free cash flow. Verizon's free cash flow supports its high dividend yield, providing income investors with a safety margin. Verizon (NYSE:VZ)’s shares dropped 6% after the telecom submitted its earnings sheet...

Freeport McMoRan (NYSE:FCX) plans to spend ~$7.5B to expand its El Abra copper mine in Chile, a project expected to take 7-8 years to develop because of permitting requirements, CEO Kathleen Quirk said Tuesday, according to Reuters. In an earnings conference call after reporting Q2 results that beat profit estimates,...

AECOM (NYSE:ACM) is well-positioned to continue delivering good growth ahead. The company's revenue growth should benefit from a healthy backlog of $23.7 billion. In addition, increasing PFAS-related work, the company's exposure to high-growth markets, and healthy infrastructure investments globally should also increase revenue growth. On the margin front, the company should benefit from improving international margins, operating leverage, and cost-saving initiatives.

My first notes on Sangamo Therapeutics, Inc. (NASDAQ:SGMO) go back to early 2014, when I was researching the “new” CRISPR gene editing companies, Editas Medicine (EDIT), Intellia Therapeutics (NTLA) and CRISPR Therapeutics (CRSP). SGMO had an old Zink Finger Protein [ZFP] technology that appeared to be potentially safer than CRISPR, but CRISPR on the surface looked like it would be able to do so much more. To me, it started to look like ZFPs might have already lost their moment, so I put SGMO in my “Needs More” file and updated it over the years.

The global cybersecurity Total Addressable Market is expected to reach $1.5 trillion to $2.0 trillion, about ten times its current size. SentinelOne's autonomous turnkey solution with affordable pricing positions it to meet the growing demand for cybersecurity. Opportunity Within the Cybersecurity Sector. With the increasing demand for protection against cyberattacks,...

Ryde is a Singaporean ride-sharing provider that went public on the NYSE in 2024, offering various services, including carpooling, ride-hailing, and parcel delivery. Despite claiming competitive advantages, Ryde has struggled to gain market share and revenue growth, facing intense competition in the industry. Ryde Group Ltd (NYSE:RYDE) is a Singaporean...

Crude oil futures fell to six-week lows Tuesday amid a broad decline in commodities, dragged down by renewed concerns over Chinese demand given the absence of further government support for the economy. "Oil bears appear to be getting in early ahead of the seasonal decline for oil prices," Exinity chief...

Crude oil futures fell to six-week lows Tuesday amid a broad decline in commodities, dragged down by renewed concerns over Chinese demand given the absence of further government support for the economy. "Oil bears appear to be getting in early ahead of the seasonal decline for oil prices," Exinity chief...

Johnson Controls International plc sells HVAC assets to Bosch in a multi-billion deal, reducing net debt while incurring substantial tax bills. The company refocused on building technologies and HVAC solutions after selling its Power Solutions business in 2018 for $13 billion, with the strategic focus sharpened further. In April, I...

Luxury brands are often mistaken for premium ones. Hermes is a true luxury brand with a $237 billion valuation, leveraging iconic products like the Birkin bag for success. Defining a luxury is a daunting task. Consumers perceive luxury in different ways, for some, it's all about the sky-high price tag,...

Medline Industries is reviewing a potential initial public offering next year that could value the medical supplies firm at $50 billion. The medical supplies company and its private equity owners are in early-stage discussion with banks about a possible listing as early as next spring, according to a Bloomberg report on Tuesday, which cited people familiar with the matter.